Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease
NCT ID: NCT00857233
Last Updated: 2012-08-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
297 participants
INTERVENTIONAL
2004-06-30
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of this 24-week open-label extension study was to collect additional long-term safety and tolerability data on memantine in patients who completed the lead-in double-blind placebo-controlled Study 10158.
In agreement with Health Canada the study was prematurely terminated due to recruitment difficulties in the lead-in Study 10158. Patients ongoing in the study when the decision to terminate was taken were allowed to complete it.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Memantine
Memantine
20 mg oral tablets once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Memantine
20 mg oral tablets once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
H. Lundbeck A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CA019
Edmonton, Alberta, Canada
CA033
Kelowna, British Columbia, Canada
CA043
Kelowna, British Columbia, Canada
CA042
Penticton, British Columbia, Canada
CA034
Winnipeg, Manitoba, Canada
CA022
Saint John, New Brunswick, Canada
CA045
Pictou, Nova Scotia, Canada
CA032
Burlington, Ontario, Canada
CA029
Orangeville, Ontario, Canada
CA004
Ottawa, Ontario, Canada
CA038
Peterborough, Ontario, Canada
CA009
Toronto, Ontario, Canada
CA005
Beauport, Quebec, Canada
CA023
Greenfield Park, Quebec, Canada
CA013
Montreal, Quebec, Canada
CA012
Sherbrooke, Quebec, Canada
CA030
Vanier, Quebec, Canada
CA017
Verdun, Quebec, Canada
CA015
Regina, Saskatchewan, Canada
CA040
Saskatoon, Saskatchewan, Canada
CA044
Chatham, , Canada
CA007
Kentville, , Canada
CA046
Kentville, , Canada
CA001
Kingston, , Canada
CA003
London, , Canada
CA002
London, , Canada
CA016
Moncton, , Canada
CA024
Montreal, , Canada
CA014
Montreal, , Canada
CA011
Montreal, , Canada
CA031
Sherbrooke, , Canada
CA006
Toronto, , Canada
CA037
Windsor, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10252
Identifier Type: -
Identifier Source: org_study_id